Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
10/20/2022 -- Results Q3 2022 -- 2.26 --
10/20/2022 08:00 EST Earnings Call Q3 2022 -- -- --
07/21/2022 08:00 EST Earnings Call Q2 2022 -- -- --
07/21/2022 -- Results Q2 2022 2.76 2.34 18.09%
04/21/2022 -- Results Q1 2022 2.76 2.66 3.60%
04/21/2022 08:00 EST Earnings Call Q1 2022 -- -- --
01/27/2022 -- Results Q4 2021 2.69 2.54 5.99%
01/27/2022 08:00 EST Earnings Call Q4 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 10/20/2022
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 07/21/2022
Beat/Miss Upgrade
Return Since 1.19%
Last FQE 06/30/2022
Next FQE 09/30/2022

Profile

Edit
In 1984, Danaher’s founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE’s Biopharma business, now called Cytiva, which added to its life sciences segment.
URL https://www.danaher.com
Investor Relations URL https://investors.danaher.com/
HQ State/Province District of Columbia
Sector Healthcare
Industry Diagnostics & Research
Equity Style Large Cap/Growth
Next Earnings Release Oct. 20, 2022
Last Earnings Release Jul. 21, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date Sep. 29, 2022

Dividends

Dividend Per Share (TTM) 0.92
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.2315
Yield to Sector 0.1843
Yield to Industry 0.8575
Last Dividend Amt. 0.25
Dividend Frequency Quarterly
Last Ex-Dividend Date Sep. 29, 2022
Yield (TTM) 0.34%
Forward Yield 0.35%
Payout Ratio 12.49%
Cash Payout Ratio 11.25%
Consistent Payer (5Y) Yes
Consistent Growth (5Y) Yes

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
9.26%
11.42%
20.01%
11.80%
49.55%
45.32%
48.57%
-13.96%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-19.66%
8.35%
31.89%
9.16%
-13.84%
31.15%
14.04%
47.86%
-24.70%
3.99%
-33.29%
70.64%
37.27%
10.61%
11.53%
2.82%
-42.56%
--
--
--
--
--
54.43%
18.78%
-20.26%
-58.68%
-88.50%
-99.97%
-99.39%
-89.16%
-15.67%
-56.75%
-57.68%
As of October 05, 2022.

Profile

Edit
In 1984, Danaher’s founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE’s Biopharma business, now called Cytiva, which added to its life sciences segment.
URL https://www.danaher.com
Investor Relations URL https://investors.danaher.com/
HQ State/Province District of Columbia
Sector Healthcare
Industry Diagnostics & Research
Equity Style Large Cap/Growth
Next Earnings Release Oct. 20, 2022
Last Earnings Release Jul. 21, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date Sep. 29, 2022

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
FSMEX 1.108B USD 14.57%
EGFFX 1.034B USD 5.39%
PRBLX 1.026B USD 4.00%
XLV 1.435B USD 3.84%
VHT 633.02M USD 3.41%
PACLX 1.229B USD 2.70%
MFELX 935.39M USD 2.64%
VGHCX 1.032B USD 2.27%
FTCS 173.32M USD 2.22%
USMV 343.94M USD 1.26%
IWD 462.94M USD 0.95%
IVW 218.71M USD 0.80%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter DHR Tweets